GLIOMARK SIGNED
Validation of blood-brain-barrier permeability as a glioma biomarker by means of the radiotracer 99mTc-tetrofosmin and single-photon emission computer tomography
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0GLIOMARK project word cloud
Explore the words cloud of the GLIOMARK project. It provides you a very rough idea of what is the project "GLIOMARK" about.
Project "GLIOMARK" data sheet
The following table provides information about the project.
| Coordinator |
CONSULTECH TECHNOLOGIEBERATUNG GMBH
Organization address contact info |
| Coordinator Country | Germany [DE] |
| Project website | http://www.gliomark.eu |
| Total cost | 4˙705˙344 € |
| EC max contribution | 4˙705˙344 € (100%) |
| Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
| Code Call | H2020-SMEINST-2-2014 |
| Funding Scheme | SME-2 |
| Starting year | 2015 |
| Duration (year-month-day) | from 2015-07-01 to 2019-12-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | CONSULTECH TECHNOLOGIEBERATUNG GMBH | DE (BERLIN) | coordinator | 3˙167˙094.00 |
| 2 | PRO-ACTINA CHIMIKI TECHNOLOGIA ANONIMI ETAIRIA | EL (MAROUSI ATHENS) | participant | 1˙538˙250.00 |
Map
Project objective
Objective of GLIOMARK is to clinically validate the permeability of the blood brain barrier (BBB) as an in vivo biomarker for the diagnosis and grading of gliomas. This will be accomplished by means of the radiotracer 99mTc-tetrofosmin (TTF) and the imaging technique Single-Photon Emission Computer To-mography (SPECT). The outcome of GLIOMARK is GlioTect, a diagnostic kit containing handling/diagnostic instructions and tetrofosmin. The latter has to be reconstituted with 99mTc pertechnetate to yield TTF, which will be used in combination with SPECT. Often computer tomography or magnetic resonance imaging are unable to detect low-grade gliomas or distinguish glioma from other diseases. Hence, brain biopsies are necessary for confirmation of diagnosis and grading of gliomas. GlioTect with TTF/SPECT enables reliable, fast differential diagnosis and grading of gliomas as non-invasive method. This has an immediate impact on the type and aggressiveness of subsequent therapies. Gliomas are recognized as a rare tumor disease with poor prognosis and orphan diagnostic designation for GlioTect will guarantee 10 years of market exclusivity upon approval. ProActina, a Greek chemical-speciality SME having identified this innovative niche market opportunity could become global market leader in glioma diagnostics. Development is at TLR level 6-7 and will be lifted to 9. Expected market application is the sale of GlioTect for preparation of TTF for use with SPECT. End users are hospitals that use the kit to reliably diagnose or exclude gliomas without the need for expensive equipment. Taken together, the aggregated unique selling point of SPECT in combination with TTF (generated by means of GlioTect) is the first ever and only glioma diagnostic, which assesses a clinically validated glioma biomarker, has high reliability, reproducibility, sensitivity, as well as specificity, which is used to replace an invasive method, is safe, well tolerated, widely available and more affordable
Deliverables
| Set up project homepage | Websites, patent fillings, videos etc. | 2019-07-25 13:49:19 |
Take a look to the deliverables list in detail: detailed list of GLIOMARK deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLIOMARK" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "GLIOMARK" are provided by the European Opendata Portal: CORDIS opendata.